In this interview, we explore the remarkable journey of Cha-Mei Tang, the Founder, President, and CEO of Creatv MicroTech, Inc., and its division Creatv Bio. She shares the story behind her pioneering work in cancer diagnostics, the discoveries that have set her company apart, and her vision for the future of cancer care. From breakthroughs in blood-based testing to the leadership principles guiding her success, Cha-Mei’s story is one of innovation, integrity, and impact.
Journey and Inspiration
Cha-Mei’s path into cancer diagnostics was shaped by curiosity and a willingness to embrace the unknown. After earning her bachelor’s, master’s, and Sc.D. degrees in Electrical Engineering and Computer Science from MIT, she began her career in theoretical physics at the Naval Research Laboratory, studying relativistic electron beams and free electron lasers.
In 1996, Cha-Mei transitioned from government research to entrepreneurship, founding Creatv MicroTech. Initially focused on microfabrication of x-ray antiscatter grids, the company evolved to include biodetection technologies. By 2010, Creatv shifted its focus to cancer diagnostics, using its microfabrication expertise to develop LifeTracDx®, a revolutionary blood test for cancer detection and monitoring.
Cha-Mei credits much of the company’s scientific advancement to Daniel L. Adams, Chief Scientific Officer, whose expertise has been instrumental in identifying novel biomarkers.
Core Values Driving Leadership
Cha-Mei’s leadership is grounded in scientific integrity, evidence-based decision making, and active listening. Every initiative at Creatv is guided by logic, data, and a commitment to improving patient outcomes.
Pioneering Leadership in 2025
What distinguishes Cha-Mei’s leadership today is her dedication to developing a spectrum of blood-based cancer diagnostics—tools that no other company currently offers, with the potential to save lives, reduce invasive procedures, and accelerate treatment decisions.
Adapting to Industry Evolution
While many companies focus on DNA, RNA, and protein markers, Creatv Bio takes a unique approach centered on Cancer-Associated Macrophage-like Cells (CAMLs)—large cells found in the blood of cancer patients but absent in healthy individuals.
Using LifeTracDx®, Creatv Bio provides a comprehensive platform for:
- Early detection
- Treatment monitoring
- Companion diagnostics
- Recurrence detection
- Tumor DNA analysis
This approach enables personalized, real-time insights without the need for invasive biopsies.
Cancer Diagnostics Unique to LifeTracDx®
LifeTracDx® delivers a spectrum of cancer diagnostic applications, benefiting both patients in treatment and those in remission.
Through analysis of CAMLs and Circulating Tumor Cells (CTCs), LifeTracDx® provides:
- Early Therapy Effectiveness
→ Determines if a patient is responding to therapy within 30 days, avoiding wasted time on ineffective treatments. - Companion Diagnostics
→ Identifies tumor markers such as PD-L1 via blood test, guiding use of immunotherapies and targeted drugs. - Cancer Aggressiveness Assessment
→ Analyzes features of CAMLs and CTCs to gauge tumor behavior at any time. - Continuous Monitoring
→ Tracks tumor changes during therapy, detecting resistance or evolution before imaging shows progression. - High-Quality Tumor DNA for Sequencing
→ Extracts unfragmented DNA from CAMLs, superior to circulating DNA fragments for mutation and amplification analysis. - End-of-Treatment Evaluation
→ Confirms whether cancer is still present, helping oncologists decide whether to continue or stop therapy. - Early Recurrence Detection
→ Detects cancer earlier than imaging, enabling prompt intervention.
Note: CAMLs have been found in over 30 tumor types, including stage 1 cancers, but never in healthy controls.
Leadership Impact
A defining moment came when Cha-Mei’s team discovered large, unusual cells while isolating CTCs. Initially overlooked by others, Daniel Adams analyzed them and identified macrophage-like markers, naming them CAMLs.
Published in PNAS (2014), this discovery became the foundation of LifeTracDx®, representing a new class of blood-based biomarkers with wide clinical applications.
Overcoming Challenges
Introducing CAMLs as a novel biomarker requires extensive education for oncologists, regulators, and payers. Cha-Mei might face hurdles in marketing, FDA navigation, and reimbursement, but persistent communication and scientific validation have steadily built awareness—further supported by the First International Polyploid Giant Cancer Cells Conference (2024).
Defining Success
For Cha-Mei, success is not measured in profits, but in solving unmet clinical needs and improving patient outcomes—turning scientific curiosity into life-saving solutions.
Looking Ahead
In 2025, Cha-Mei’s mission is to expand awareness and establish a CLIA-certified laboratory for clinical testing. Over the next five years, she aims to:
- Secure FDA approvals
- Partner with pharmaceutical companies for drug development support
- Collaborate with global organizations to make LifeTracDx® accessible worldwide
In conclusion, Cha-Mei Tang’s journey embodies the spirit of innovation—guided by curiosity, fueled by science, and driven by a mission to save lives. Through her leadership, Creatv Bio stands at the forefront of cancer diagnostics, offering a vision of a future where blood tests guide treatment, detect recurrence early, and bring hope to millions.
